4.5 Article

Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0127

关键词

-

类别

资金

  1. Eisai, Inc.
  2. Millennium: The Takeda Oncology Company
  3. Teva Pharmaceuticals
  4. Bayer HealthCare Pharmaceuticals Inc.
  5. Celgene Corporation
  6. Endo Pharmaceuticals and HealthTronics
  7. Genentech
  8. ARIAD Pharmaceuticals, Inc.

向作者/读者索取更多资源

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据